久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Zydus Cadila gets US FDA nod for Liothyronine Sodium Tablets

expresspharmaJanuary 25, 2021

Tag: FDA , liothyronine , Zydus Cadila

Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 meg, 25 meg, and 50 meg (US RLD: Cytomel Tablets).

Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Aurobindo, KAPL, Kinvan get approval under PLI scheme

Next:Fiocruz Institute, Brazil commences distribution of India-made AstraZeneca COVID-19 vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service